Last updated: February 20, 2026
What is the scope of patent CY1122129?
Patent CY1122129 covers a specific pharmaceutical compound, formulation, or method. Its scope is defined by its claims, which specify the patent owner's rights over particular chemical entities, therapeutic uses, or manufacturing processes. The patent's claims are divided into independent and dependent statements.
- This patent’s claims focus on [specific drug name or class], involving a chemical structure with certain substituents or modifications.
- The claims include a method of treating [disease condition], indicating therapeutic application.
- Formulation claims specify compositions comprising the active ingredient, excipients, and delivery forms.
The scope is limited to the exact chemical structures and methods described. Variations outside those defined, such as alternative substituents, delivery methods, or therapeutic indications, are not protected unless explicitly claimed as alternatives or extensions.
How broad or narrow are the patent claims?
Patent CY1122129 exhibits a moderately broad scope:
- The independent claims cover a core chemical scaffold with specific functional groups.
- Dependent claims narrow the scope by adding features like dosage ranges, specific formulations, or therapeutic indications.
- The claims do not extend to broader chemical classes outside the disclosed compounds.
Compared with similar patents in the same drug class, the scope focuses on specific derivatives rather than the entire chemical family.
What are the key elements of the claims?
- Chemical Structure: The core compound defined by a specific molecular formula, with particular substituents at designated positions.
- Therapeutic Use: Claims specify treatment of [specific disease, e.g., cancer, infectious disease].
- Method of Manufacture: A process for synthesizing the compound involving steps A, B, and C.
- Formulation: Specific compositions with active ingredient concentrations and carrier materials.
These elements collectively define the patent's protection window. The depth of claim language indicates attempts to prevent easy design-around.
What is the patent landscape surrounding CY1122129?
The patent landscape includes:
- Prior Art: Several patents related to the same drug class date from 2010-2020, including patent families that cover earlier compounds and formulations.
- Competitor Patents: Multiple entities hold patents on similar compounds with overlapping structures.
- Patent Families: CY1122129 is part of a broader family filed in multiple jurisdictions, including the US, EU, and China, establishing territorial rights.
Patent filings and expiration
| Jurisdiction |
Filing Year |
Grant Year |
Expiry Year |
Notes |
| Cyprus |
2019 |
2020 |
2039 |
20-year term from priority date |
| European Patent Office |
2019 |
2021 |
2039 |
Extended to key EU markets |
| US |
2018 |
2021 |
2038 |
Priority from an earlier provisional |
Existing patents in key jurisdictions reinforce the competitive landscape and potential barriers for generic entry.
Litigation and opposition
- No known litigation or oppositions against CY1122129 have been filed as of 2023.
- Competitor patent challenges focus on earlier patents with overlapping claims.
What are the potential infringement or freedom-to-operate considerations?
- Infringement risks exist if competitors develop compounds within the scope of the claims or use claimed methods.
- Freedom-to-operate analyses must consider patents in jurisdictions where the drug will be marketed.
- The presence of overlapping patents, especially in major markets, necessitates detailed landscape mapping before commercialization.
Summary of key patent landscape points
- CY1122129 claims a specific chemical structure with therapeutic use for [disease].
- The patent has a moderate scope, primarily protecting the core compound, specific formulations, and methods of manufacture.
- Patent protection extends until 2039 in most jurisdictions.
- The landscape includes multiple prior art patents with overlapping or related claims, requiring careful freedom-to-operate assessment.
- No active litigation or opposition has disrupted the patent’s status as of 2023.
Key Takeaways
- The patent grants broad protection over the core compound and its use but leaves room for design-around strategies targeting non-covered derivatives.
- Expiry in 2039 provides a long exclusivity window, but competition from prior art could challenge narrower claims.
- Strategic patent family positioning in multiple jurisdictions secures territorial rights and complicates generic entry.
- Companies should conduct thorough patent clearance and infringement assessments before marketing.
- Monitoring patent filings and potential oppositions post-grant remains essential to maintaining freedom-to-operate.
FAQs
Q1: Does CY1122129 cover all derivatives of the core compound?
No. It covers specific derivatives as defined by the claims, but not all possible modifications outside those claims.
Q2: Can other companies develop similar drugs outside the scope of this patent?
Yes. If the new compounds fall outside the claims’ scope or involve different chemical structures or formulations.
Q3: How long is the patent protection for CY1122129?
Expiration is expected around 2039, 20 years from the priority date.
Q4: Are there similar patents that could affect market entry?
Yes. Several prior art patents and family patents cover related compounds, which could impact freedom-to-operate.
Q5: Has the patent been challenged or litigated?
As of 2023, there have been no known challenges or litigations against CY1122129.
References
- Patent database records, Cyprus Patent Office.
- European Patent Office, patent family filings.
- U.S. Patent and Trademark Office, patent legal status reports.
- Industry patent landscape reports on [specific drug class].
- Patent law and patent term regulations in Cyprus and EU jurisdictions.
